Newsroom
Sorted by: Latest
-
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients
CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Capital Strength ESG Leaders UCITS ETF 24.04.2026 FCSG IE00BKPSPT20 1,025,002.00 USD 43,523,547.14 42.462 ...
-
DocGo to Announce First Quarter 2026 Results on Monday, May 11, 2026
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled medical transportation and mobile health services, announced today that the Company will release its financial results for the first quarter ended March 31, 2026 after the markets close on Monday, May 11, 2026. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Monday, May 11, 2026 5:00 p.m....
-
AIG Completes Its Planned CEO Transition Plan
NEW YORK--(BUSINESS WIRE)--The AIG Board of Directors announced today that effective June 1, 2026, Eric Andersen will become President and Chief Executive Officer of AIG and join the AIG Board of Directors and Peter Zaffino will become Executive Chair of the AIG Board of Directors, marking the successful conclusion of the company’s previously announced leadership transition plan. “I want to express my appreciation and gratitude to Peter Zaffino for his tremendous leadership, tireless commitment...
-
Presidio Announces First Quarter 2026 Earnings Results Conference Call
FORT WORTH, Texas--(BUSINESS WIRE)--Presidio Production Company (NYSE: FTW) (“Presidio” or the “Company”), a yield-focused, differentiated oil and gas operator in the United States focused on the acquisition and optimization of producing oil and natural gas wells, without drilling, today announced that it will report first quarter 2026 results on Friday, May 15th, 2026. The Company will host an earnings conference call that morning at 11:00 AM ET / 10:00 AM CT to discuss financial results and b...
-
ISS Joins Glass Lewis and Egan-Jones by Supporting Impactive’s Case for Change at WEX
NEW YORK--(BUSINESS WIRE)--Impactive Capital, LP (“Impactive” or “we”), together with its affiliates, is one of the largest shareholders of WEX Inc. (NYSE: WEX) (the “Company” or “WEX”) with an ownership interest of approximately 4.9%. Impactive announced today that leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended that shareholders vote on the WHITE proxy card FOR the election of Impactive director nominees Kurt Adams and Lauren Taylor Wolfe to the Com...
-
Sharon AI Enters Into Definitive Agreements for US$350 Million Convertible Note Offering to Expand GPU and Network Procurement
NEW YORK--(BUSINESS WIRE)--Today, SharonAI Holdings Inc. (NASDAQ:SHAZ) and its subsidiaries (“Sharon AI” or “the Company”), a leading Australian Neocloud, announced that it has entered into definitive agreements for the purchase of US$350 million of 6% Convertible Senior Notes due in 2031 (the “Notes”). The issue price for the Notes will equal 100% of the principal amount thereof. The Notes will be sold in a private offering pursuant to Rule 4(a)(2) of the Securities Act of 1933, as amended (th...
-
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS® System Post-Approval Study (PAS) in Neurology, alongside the Company’s recent presentation of 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meet...
-
S&K Companies Awarded Missile Defense Agency SHIELD IDIQ Contracts
POLSON, Mont.--(BUSINESS WIRE)--S&K Global Solutions, LLC is pleased to announce it was awarded a contract for the Missile Defense Agency Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract with a ceiling of $151B. This contract encompasses a broad range of work areas that allows for the rapid delivery of innovative capabilities to the warfighter with increased speed and agility. Under this vehicle, S&K Global Solution...
-
Riassunto: Prodalim amplia la piattaforma tecnologica negli Stati Uniti con nuove operazioni in California
WINTER GARDEN, Fla.--(BUSINESS WIRE)--Prodalim, un leader globale nelle soluzioni di succhi e ingredienti speciali, ha reso nota oggi l'espansione della sua piattaforma Solos negli Stati Uniti con il lancio delle operazioni nel nuovo impianto di Hopland, California. Il nuovo sito segna una tappa importante nella continua globalizzazione di Solos, la piattaforma brevettata di innovazione nelle bevande e recupero degli aromi di Prodalim e mette Solos al centro di una delle zone di produzione di v...